Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

contract proof-of-concept manufacturing cell-therapy biopharmaceutical oncology biotech

More Like This

SmartCella obtains approval for GMP manufacturing and quality control testing of cell therapies

PR Newswire associated0

Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform

PR Newswire associated0

Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm's Innovative T Cell Therapies for Solid Cancers

Mytos Co-Founders: Ali Afshar, Ph.D (left), CEO and Ignacio Willats (right). Photo credit: Mytos

Mytos Announces $19M Series A Funding to Automate Human Cell Manufacturing and Further Accelerate Growth

T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

PR Newswire associated0

Minaris Advanced Therapies launches as the leading global partner dedicated to cell therapy development, manufacturing, and testing

BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell